Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Celgene thinks its Otezla pill will be easy for the market to swallow

24.03.2014 / Fierce Pharma

With its FDA approval for psoriatic arthritis, Celgene's Otezla (apremilast) comes into a market dominated by some of the best-selling drugs in the world, including AbbVie's top seller Humira and Enbrel from Amgen and Pfizer. But instead of an injection, Celgene's drug is a pill, an advantage the company thinks will help it eventually reach up to $2 billion in sales–a figure analysts feel less certain about.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: